Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02567110 · ClinicalTrials.gov registry record
Magnetic Resonance Spectroscopy (MRS) in Midlife Depression
A clinical trial, sponsored by Emory University.
- Completed
- Registry status
- 169
- Enrollment target
NCT02567110 is a clinical trial that has completed, run by Emory University. The registered enrollment target is 169 participants.
The verdict
NCT02567110 has completed, sponsored by Emory University.
- COMPLETED
- Registry status
- 169 participants
- Enrollment target
Study Summary
The purpose of this study is to determine the impact of inflammation on central nervous system (CNS) glutamate, white matter pathology and alterations in behavior and cognition in middle-aged patients with major depression. Depression is associated with significant alterations in glutamate concentrations and white matter integrity, which has been associated with decreased antidepressant response, poor functional outcome, and cognitive impairment.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 169 participants |
| Start Date | 2016-07 |
| Est. Completion | 2022-02-04 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02567110
The ClinicalTrials.gov registry entry for NCT02567110 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 169 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Emory University, which has 1,208 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 0 interventions.
NCT02567110 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02567110 about?
NCT02567110 is a clinical study titled "Magnetic Resonance Spectroscopy (MRS) in Midlife Depression". The purpose of this study is to determine the impact of inflammation on central nervous system (CNS) glutamate, white matter pathology and alterations in behavior and cognition in middle-aged patients with major depression. Depression is associated with significant alterations in glutamate concentra...
What is the current status of trial NCT02567110?
This trial is currently completed. The enrollment target is 169 participants. The study started on 2016-07. Estimated completion is 2022-02-04.
Who is sponsoring clinical trial NCT02567110?
This trial is sponsored by Emory University, which has 1,208 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.